Dina Chaya is a Partner with NeoMed Management.

She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i in London and Index Ventures in Geneva, her successful investments include Wilson Therapeutics ($855 million acquisition by Alexion Pharmaceuticals), EUSA Pharma ($700 million acquisition by Jazz Pharmaceuticals), Endosense ($330 million acquisition by St Jude Medical) and Novexel ($500 million acquisition by AstraZeneca). 

Dina currently serves on the board of directors of Imago BioSciences, Spruce Biosciences, Anjarium Biosciences and Oxular. 

She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France and carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.